Activated PI3K Delta Syndrome

Activated PI3K Delta Syndrome (APDS) is a rare primary immunodeficiency disorder characterized by mutations in the phosphoinositide 3-kinase delta (PI3Kδ) gene. This condition leads to abnormal immune system function, making individuals susceptible to recurrent infections, autoimmunity, and lymphoproliferation. APDS is a genetic condition that affects both children and adults, with symptoms often appearing in early childhood.

Etiology

APDS is caused by gain-of-function mutations in the PIK3CD gene, which encodes the p110δ subunit of PI3Kδ, or in the PIK3R1 gene, encoding the p85α regulatory subunit. These mutations lead to hyperactivation of the PI3Kδ pathway, which is crucial for the activation, development, and function of B cells and T cells. The result is an imbalance in immune system regulation, contributing to the clinical manifestations of the syndrome.

Clinical Manifestations

The clinical presentation of APDS can vary widely among affected individuals but commonly includes:

• Recurrent infections: Patients often experience recurrent respiratory infections, sinusitis, and otitis media. These infections are typically caused by encapsulated bacteria due to impaired antibody production.
• Lymphoproliferation: Enlargement of lymph nodes (lymphadenopathy), spleen (splenomegaly), and sometimes the liver (hepatomegaly) are common.
• Autoimmunity: Autoimmune disorders, such as autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune thyroiditis, can occur.
• Bronchiectasis: Chronic lung disease due to recurrent infections can lead to bronchiectasis, a condition characterized by permanent enlargement of parts of the airways of the lung.

Diagnosis

Diagnosis of APDS is based on clinical presentation, immunological findings, and genetic testing. Immunological tests may reveal elevated levels of IgM, reduced levels of IgG and IgA, and impaired vaccine responses. Genetic testing confirms the presence of mutations in the PIK3CD or PIK3R1 genes.

Treatment

Treatment of APDS focuses on managing infections, preventing complications, and addressing immune dysregulation. Management strategies include:

• Immunoglobulin replacement therapy: To prevent infections by providing the antibodies that the patient's body cannot produce adequately.
• Antibiotic prophylaxis: Long-term antibiotics may be used to prevent bacterial infections.
• Immunosuppressive therapy: Medications such as rituximab may be used to control autoimmune manifestations and lymphoproliferation.
• PI3Kδ inhibitors: Specific inhibitors targeting the PI3Kδ pathway are under investigation and have shown promise in managing symptoms and improving quality of life in patients with APDS.

Prognosis

The prognosis for individuals with APDS varies depending on the severity of symptoms and the effectiveness of management strategies. Early diagnosis and appropriate treatment can significantly improve outcomes, although patients may still experience complications related to the disease and its treatment.

Research Directions

Research on APDS is focused on understanding the underlying mechanisms of the disease, identifying new therapeutic targets, and developing more effective treatments. Clinical trials are ongoing to evaluate the safety and efficacy of PI3Kδ inhibitors and other novel therapies.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian